share_log

Panbela Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Panbela Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

Panbela Therapeutics | DEFR14A：修正后委托征集材料
美股sec公告 ·  05/06 16:17
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. has filed a definitive proxy statement with the SEC to amend its original proxy statement regarding its Special Meeting of Stockholders, now rescheduled from May 3, 2024, to May 28, 2024. The amendment reflects the rescheduling, a change in the record date for determining stockholders entitled to vote from March 27, 2024, to April 24, 2024, and the issuance of one share of Series A Preferred Stock with specific voting rights. The Special Meeting's agenda includes a proposal for a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to increase the per-share market price to meet national securities exchange listing requirements following Nasdaq's notification of delisting. Stockholders are urged to vote using the new proxy card provided, as previous ones will be disregarded. The meeting will be held virtually, and stockholders must register by May 25, 2024, to attend.
Panbela Therapeutics, Inc. has filed a definitive proxy statement with the SEC to amend its original proxy statement regarding its Special Meeting of Stockholders, now rescheduled from May 3, 2024, to May 28, 2024. The amendment reflects the rescheduling, a change in the record date for determining stockholders entitled to vote from March 27, 2024, to April 24, 2024, and the issuance of one share of Series A Preferred Stock with specific voting rights. The Special Meeting's agenda includes a proposal for a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-45, as determined by the Board, and the potential adjournment of the meeting if necessary to solicit additional proxies. The reverse stock split aims to increase the per-share market price to meet national securities exchange listing requirements following Nasdaq's notification of delisting. Stockholders are urged to vote using the new proxy card provided, as previous ones will be disregarded. The meeting will be held virtually, and stockholders must register by May 25, 2024, to attend.
Panbela Therapeutics, Inc.已向美国证券交易委员会提交了最终委托书，以修改其关于其股东特别会议的原始委托声明，该特别会议现已从2024年5月3日改期至2024年5月28日。该修正案反映了重新安排、确定有权投票的股东的记录日期从2024年3月27日更改至2024年4月24日，以及发行一股具有特定投票权的A系列优先股。特别会议的议程包括一项提案，由董事会决定，以1比10和1比45的比例对普通股进行反向拆分，以及在必要时可能休会以征集更多代理人。反向股票拆分旨在提高每股市场价格，以满足纳斯达克退市通知后的国家证券交易所上市要求。敦促股东使用提供的新代理卡进行投票，因为以前的代理卡将被忽略。会议将以虚拟方式举行，股东必须在2024年5月25日之前注册才能参加。
Panbela Therapeutics, Inc.已向美国证券交易委员会提交了最终委托书，以修改其关于其股东特别会议的原始委托声明，该特别会议现已从2024年5月3日改期至2024年5月28日。该修正案反映了重新安排、确定有权投票的股东的记录日期从2024年3月27日更改至2024年4月24日，以及发行一股具有特定投票权的A系列优先股。特别会议的议程包括一项提案，由董事会决定，以1比10和1比45的比例对普通股进行反向拆分，以及在必要时可能休会以征集更多代理人。反向股票拆分旨在提高每股市场价格，以满足纳斯达克退市通知后的国家证券交易所上市要求。敦促股东使用提供的新代理卡进行投票，因为以前的代理卡将被忽略。会议将以虚拟方式举行，股东必须在2024年5月25日之前注册才能参加。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息